

THC Therapeutics, Inc.

A Nevada Corporation

QUARTERLY DISCLOSURE STATEMENT **Quarter Ended January 31, 2017**

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities in the past five years and the dates of the name changes.

THC Therapeutics, Inc. (formerly Harmonic Energy, Inc. until Feb. 7, 2017)

2) Address of the issuer's principal executive offices

Company Headquarters

Address 1: 11700 W Charleston Blvd. #73

Address 2: Las Vegas, NV 89135

Phone: 702-602-8422

Email: info@thctherapeutics.com

Website(s): http://www.thctherapeutics.com

3) Security Information

Trading Symbol: THCT

Exact title and class of securities outstanding: common stock, par value \$0.001

CUSIP: 87243Y 109

Par or Stated Value: \$0.001

Total shares authorized: 500,000,000 as of: 3/22/17

Total shares outstanding: 115,363,942 as of: 3/22/17

Transfer Agent

Name: Island Stock Transfer

Address 1: 15500 Roosevelt Blvd.

Address 2: Clearwater, FL 33760

Phone: (727) 289-0010

Is the Transfer Agent registered under the Exchange Act?* Yes: ☒ No: ☐

*To be included in the OTC Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

List any restrictions on the transfer of security:

none

Describe any trading suspension orders issued by the SEC in the past 12 months.

none

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

Effective June 10, 2016, the issuer conducted a 1 for 14 reverse split of its issued and outstanding common stock.

4) Issuance History

List below any events, in chronological order, that resulted in changes in total shares outstanding by the issuer in the past two fiscal years and any interim period. The list shall include all offerings of equity securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services, describing (1) the securities, (2) the persons or entities to whom such securities were issued and (3) the services provided by such persons or entities.

Effective June 10, 2016, the issuer conducted a 1 for 14 reverse split of its issued and outstanding common stock.

Effective July 20, 2016, the issuer entered into a Debt Conversion Agreement (the "Agreement") with its President and CEO, Jamie Mann. Under the Agreement Mr. Mann and the Company agreed to convert \$225,000 in consulting fees due and owing by the Company to Mr. Mann's consulting firm into shares of common stock at a price of \$0.0703 per share. In extinguishment of the debt owed, Mr. Mann was issued a total of 3,200,569 shares.

On January 20, 2017, the issuer entered into an Asset Purchase Agreement (the "Agreement") with its CEO, Brandon Romanek. Under the Agreement, the issuer acquired certain patent applications, trademark applications, and web domain names from Mr. Romanek. In exchange, Mr. Romanek was issued 100,000,000 shares of common stock and 2,000,000 shares of our Series A Preferred Stock.

On February 7, 2017, a \$10,000 portion of a convertible note payable was converted to 10,000,000 shares of common stock.

5) Financial Statements

The Company has filed the following financial statements in connection with this Quarterly Disclosure Statement, which are incorporated by reference:

Quarterly Report for the quarter ended January 31, 2017

6) Describe the Issuer's Business, Products and Services

Describe the issuer's business so a potential investor can clearly understand the company. In answering this item, please include the following:

A. a description of the issuer's business operations;

We are a publicly traded health and healing company in the Cannabis space. We are dedicated to innovating new methods and refining current industry standards within the Cannabis market. We are forward thinking and hold, Better Health Through The Science of Nature as our guiding statement. We are currently in product development on the dHydronator®, a sanitizing herb dryer, and a subsequent product line to follow up after the dHydronator's release. Our plan for future growth includes: cultivation, dispensing, extractions, infusions, topical remedies, edibles, research and testing facilities, personal wellness centers, and flotation therapy.

B. Date and State (or Jurisdiction) of Incorporation:

May 1, 2007; Nevada

C. the issuer's primary and secondary SIC Codes;

3721

D. the issuer's fiscal year end date;

7/31

E. principal products or services, and their markets;

The Company is in product development on the dHydronator®, a sanitizing herb dryer to be marketed initially to the legal cannabis industry.

7) Describe the Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The Company does not currently own or lease any real property.

8) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant shareholders.

A. Names of Officers, Directors, and Control Persons. In responding to this item, please provide the names of each of the issuer's executive officers, directors, general partners and control persons (control persons are beneficial owners of more than five percent (5%) of any class of the issuer's equity securities), as of the date of this information statement.

Name	Office
Brandon Romanek	President, CEO, CFO, and sole Director

B. Legal/Disciplinary History. Please identify whether any of the foregoing persons have, in the last five years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

None

- C. Beneficial Shareholders. Provide a list of the name, address and shareholdings or the percentage of shares owned by all persons beneficially owning more than ten percent (10%) of any class of the issuer's equity securities. If any of the beneficial shareholders are corporate shareholders, provide the name and address of the person(s) owning or controlling such corporate shareholders and the resident agents of the corporate shareholders.

Name	Shares	Percent of Class
Brandon Romanek	305,316,322 ⁽¹⁾	96.8%

⁽¹⁾ Consists of 105,316,322 shares of common stock, and 2,000,000 shares of Series A Preferred Stock convertible to 200,00,000 shares of common stock

9) Third Party Providers

Please provide the name, address, telephone number, and email address of each of the following outside providers that advise your company on matters relating to operations, business development and disclosure:

Legal Counsel

Name: Joe Laxague, Esq.

Firm: Laxague Law, Inc.

Address 1: 1 East Liberty, Suite 600

Address 2: Reno, NV 89501

Phone: (775) 234-5221

Email: joe@laxaguelaw.com

Accountant or Auditor

Name: Michael Bingham

Firm: Bingham & Company

Address 1: 300-1275 West 6th

Address 2: Vancouver, BC V6H 1A6

Investor Relations Consultant

None.

Other Advisor: Any other advisor(s) that assisted, advised, prepared or provided information with respect to this disclosure statement.

None.

10) Issuer Certification

I, Brandon Romanek, certify that:

1. I have reviewed this Quarterly Disclosure Statement of THC Therapeutics, Inc.;

2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and

3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

March 22, 2017



Brandon Romanek, CEO and CFO